November 8, 2014
Title: Bartholomew the apostle: the saint of dermatology
Journal: JAMA Dermatol
Short Title: Bartholomew the apostle: the saint of dermatology
Alternate Journal: JAMA dermatology
ISSN: 2168-6084 (Electronic)
Accession Number: 24132316
*Religion and Medicine
Notes: Lee, Kachiu C
JAMA Dermatol. 2013 Oct;149(10):1194. doi: 10.1001/jamadermatol.2013.6135.
Author Address: Brown University, Providence, Rhode Island.
Reference Type: Journal Article
Record Number: 4467Author: Li, J., Chong, A. H., Green, J., Kelly, R. and Baker, C.
Title: Mycophenolate use in dermatology: a clinical audit
Journal: Australas J Dermatol
Short Title: Mycophenolate use in dermatology: a clinical audit
Alternate Journal: The Australasian journal of dermatology
ISSN: 1440-0960 (Electronic)
Accession Number: 23574297
Aged, 80 and over
Dermatitis, Atopic/*drug therapy
Immunosuppressive Agents/*therapeutic use
Mycophenolic Acid/adverse effects/*analogs & derivatives/therapeutic use
Pyoderma Gangrenosum/*drug therapy
Abstract: Mycophenolate use in dermatology is growing due to its reputation as a steroid-sparing agent with a favourable side-effect profile. However, there are limited data on the efficacy and tolerability of mycophenolate for many dermatological indications. We conducted a retrospective clinical audit in 33 dermatology patients who had received mycophenolate at our institution between April 2010 and January 2012. The top indication was pyoderma gangrenosum (14 patients) followed by atopic dermatitis (seven patients). Overall 70 per cent of patients showed some benefit from mycophenolate treatment, with 12 per cent failing to respond. Side-effects were experienced by 45 per cent of patients, two of whom had serious side-effects. Female sex appears to be a risk factor for adverse effects. We conclude that although mycophenolate is a promising agent across a variety of dermatological conditions, further randomised controlled trials are required.